Search results
BIOPHEN DiXaI (Direct Xa Inhibitors)
Measurement of rivaroxaban and other factor Xa inhibitors in citrated plasma or other biological fluids. Note: BIOPHEN Heparin LRT and BIOPHEN Heparin (3 or 6) can also be used for testing direct factor Xa inhibitors (DiXaIs), such as rivaroxaban, apixaban or edoxaban. Adjusted protocols are available on demand.
BIOPHEN Antithrombin 5 (anti-Xa)
Diagnosis of congenital or acquired antithrombin deficiencies. Measurement of AT activity in biological milieu or purified fractions.
BIOPHEN Antithrombin 2.5 (Anti-Xa)
Diagnosis of congenital or acquired antithrombin deficiencies. Measurement of AT activity in biological milieu or purified fractions.
BIOPHEN α2-Antiplasmin (Plasmin Inhibitor) LRT
Assay proposed for the measurement of plasmin inhibitor (α2-antiplasmin) activity in research applications.
BIOPHEN Plasminogen LRT
Assay of plasminogen in human plasma for the diagnosis of congenital or acquired plasminogen deficiencies. An abnormal plasminogen activity is an indicator for fibrinolytic troubles.
BIOPHEN Heparin anti-IIa (2-stages) -> SEE NEW REF. 220005
Assay proposed for the measurement of heparin anti-thrombin activity in research applications acc. to Pharmacopoeia.
BIOPHEN Heparin (anti-Xa, 2-stages kit) -> SEE NEW REF. 221005
Assay proposed for the measurement of anti-Xa heparin activity in research applications. This assay meets USP/EP requirements.
BIOPHEN Factor VIIa
Assay proposed for the measurement of factor VIIa activity in research applications.
Factor VII Deficient Plasma
Measurement of factor VII (FVII / proaccelerin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FVII deficient plasma is required
CRYOcheck Factor VII Deficient Plasma, frozen
Deficient substrate for clot-based factor VII assays.